Axogen, Inc. key statistics and ratios
In fiscal 2025, Axogen, Inc. had return on equity of -13.5%, an operating margin of -3.5%, debt equal to 37.6% of equity and a current ratio of 5.11. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 54.1% | 50.0% | 74.5% | 77.7% | 79.5% | 82.3% | 84.3% | 84.6% | 84.6% | 83.7% | 80.8% | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% | 74.2% |
| Operating margin | −149.2% | −143.7% | −101.4% | −87.6% | −58.3% | −33.9% | −19.8% | −13.2% | −24.4% | −29.4% | −20.6% | −20.0% | −21.4% | −13.5% | −1.8% | −3.5% | −5.2% |
| Net margin | −180.5% | −190.1% | −122.4% | −133.0% | −105.3% | −48.9% | −35.1% | −17.3% | −26.7% | −27.3% | −21.2% | −21.2% | −20.9% | −13.7% | −5.3% | −7.0% | −12.0% |
| Free-cash-flow margin | — | −146.4% | −113.2% | −97.0% | −65.4% | −49.3% | −29.6% | −17.1% | −28.8% | −23.0% | −28.1% | −32.4% | −26.1% | −12.3% | 0.8% | −1.3% | 8.3% |
| Return on equity | — | — | — | — | — | — | −124.7% | −52.1% | −26.0% | −20.9% | −18.6% | −22.9% | −27.1% | −22.1% | −10.0% | −13.5% | −10.2% |
| Return on assets | −84.7% | −97.6% | −57.6% | −60.8% | −80.3% | −50.3% | −34.7% | −19.9% | −20.4% | −18.5% | −13.4% | −13.2% | −14.4% | −11.1% | −5.0% | −7.4% | −8.3% |
| Asset turnover | 0.47 | 0.51 | 0.47 | 0.46 | 0.76 | 1.03 | 0.99 | 1.15 | 0.77 | 0.68 | 0.63 | 0.62 | 0.69 | 0.81 | 0.94 | 1.06 | 0.69 |
| Current ratio | 0.56 | 5.39 | 12.36 | 12.23 | 5.89 | 9.45 | 3.97 | 4.06 | 11.57 | 6.47 | 6.36 | 5.23 | 4.13 | 2.89 | 3.24 | 5.11 | 12.02 |
| Debt to equity | — | 82.4% | — | >999% | — | 301.4% | 162.9% | 97.5% | 0.0% | 1.3% | 28.4% | 39.8% | 45.3% | 48.7% | 45.7% | 37.6% | 0.0% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m |
| R&D as % of revenue | 14.5% | 14.4% | 18.6% | 19.4% | 18.0% | 11.8% | 10.2% | 11.1% | 14.0% | 16.4% | 15.9% | 19.0% | 18.5% | 17.2% | 14.8% | 14.6% | 14.0% |
| Capital spending as % of revenue | — | 0.4% | 0.6% | 1.6% | 3.2% | 1.5% | 2.3% | 1.8% | 7.5% | 4.4% | 19.5% | 21.8% | 14.5% | 8.7% | 1.7% | 1.7% | 2.4% |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 76.1% | 71.9% | 74.2% | 76.6% | 74.1% | 75.2% | 72.7% | 74.8% |
| Operating margin | 4.1% | −3.4% | 3.0% | 3.2% | −16.3% | −4.6% | −3.1% | 1.3% |
| Net margin | 0.9% | −7.9% | 1.0% | 1.2% | −22.0% | −31.9% | −2.2% | 3.1% |
| Free-cash-flow margin | 16.3% | −27.7% | 12.4% | 2.8% | 3.0% | −2.0% | 9.1% | 20.0% |
| Current ratio | 3.24 | 4.28 | 4.14 | 4.09 | 5.11 | 7.10 | 6.60 | 12.02 |
| Debt to equity | 45.7% | 45.3% | 42.7% | 39.9% | 37.6% | 0.0% | 0.0% | 0.0% |
| R&D as % of revenue | 13.6% | 12.5% | 12.1% | 12.6% | 20.7% | 12.2% | 12.3% | 11.8% |
Financial health
- Short-term assets cover short-term liabilities $438m of assets due within a year against $36m of liabilities due within a year.
- Short-term assets cover long-term liabilities $438m short-term assets against $18m of longer-dated liabilities.
- More cash than debt $329m of cash against $0 of debt.
- Debt below 40% of shareholders' equity Debt is 0% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 43% to 0% over five years.
- A year's operating cash flow covers at least 20% of debt No debt to cover.
- Operating profit covers interest at least five times over Operating income of −$14m against $2m of interest.
Moat
Weak moat
How hard Axogen's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Cash operating profit has been a median -2.3% of total assets over 10 years.
- Pricing power 18 / 20
Gross margin has been a median 81.3%, moving by 4.2 percentage points (standard deviation) across 10 years.
- Durability 10 / 20
Operating margin has been a median -18.0%; its worst year was -29.3%.
- Cash conversion 2 / 20
Free cash flow was positive in 2 of 10 years, at a median -22.1% of revenue.
- Discipline 1 / 20
The diluted share count rose 27.4% over five years; stock-based pay has been a median 9.0% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Orthopediatrics Corp statistics
- Lemaitre Vascular Inc statistics
- Cerus Corp statistics
- Establishment Labs Holdings Inc. statistics
- Skinhealth Systems Inc. statistics
Head to head: AXGN vs KIDSAXGN vs LMATAXGN vs CERSAXGN vs SKIN
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies